Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
DOI: 10.54254/2753-8818/24/20231153

Causation of non-small lung cancer by tyrosine kinase mutation mechanism and its target drug designs and improvements

Zehua Liu

State university of New York at Buffalo, Albany, NY 12246, USA

zehualiu2333@gmail.com

Abstract. Tyrosine kinase receptor dysregulation is closely associated with diseases such as non-small cell lung cancer (nsclc). Since small molecule inhibitors are able to target the tyrosine kinase receptor and limit its oncogenic activity, the development of targeted drugs has also been a focus of research. This article summarizes the relationship between tyrosine kinase receptors and non-small cell lung cancer, discusses the impact of specific molecular abnormalities in lung cancer on targeted therapies, and the progress of the inhibitor emergency. An integrated approach to treatment will help develop more effective treatment plans for patients that include molecular analysis, targeted therapy, and drug resistance. In addition, the article discusses the impact of personalized care on improving patient health.

Keywords: Tyrosine Kinase, Non-Small Lung Cancer, Target Drug, Inhibitors.

1. Introduction

Tyrosine kinase receptors are required for several biological activities, such as cell growth, proliferation, and survival. These receptors' dysregulation has been associated with various cancers, including non-small cell lung cancer (NSCLC). Scientists have been working hard to create targeted drugs that block the abnormal signaling pathways of tyrosine kinase receptors, which are related to non-small cell lung cancer (NSCLC). Because of their capacity to target tyrosine kinase receptors and limit their oncogenic activity, small molecule inhibitors have emerged as a viable therapeutic treatments. These inhibitors have gone through several generations, each with its own set of improvements and features. The present state of knowledge about the relationship between tyrosine kinase receptors and non-small cell lung cancer is summarized in this article, focusing on the advances gained employing small molecule inhibitors of successive generations. Targeted treatments for NSCLC may improve patient outcomes in the future, but only if the characteristics and benefits of these inhibitors are well known.

The complexity and diversity of cancer make diagnosis and treatment difficult. This article summarizes the most recent findings and clinical applications in oncology, focusing on lung cancer. The evaluation of targeted drugs, molecular profiling, and the challenges of resistance are only a few of the topics covered in the selected research and books on lung cancer management. These studies are part of a more significant effort to improve lung cancer patient's odds of survival through individualized treatment.

DOI: 10.54254/2753-8818/24/20231153

This article's first category of research examines the potential advantages and dangers of targeted therapy for advanced solid tumors. ALKS 4230 is a fusion protein that has only studied once for its medicinal potential. In patients with EGFR-mutant metastatic lung adenocarcinoma, afatinib, an EGFR tyrosine kinase inhibitor, was compared to cisplatin plus pemetrexed. These studies show that targeted medicines can improve the prognosis of patients with advanced solid tumors, demonstrating the importance of customized therapy regimens.

Specific molecular anomalies in lung cancer and their implications for targeted therapy are also fully covered in this review. The clinical value of routine molecular profiling in guiding treatment decisions is highlighted in a study that provides a complete molecular profiling method for patients with advanced non-small cell lung cancer (NSCLC). A book claims that epidermal growth factor receptor (EGFR) inhibitors are critical in treating advanced NSCLC with EGFR mutations. These results, which pave the path for personalized medicine in lung cancer treatment, highlight the importance of molecular profiling and targeted therapy in improving patient outcomes.

2. Literature review

A study by Infantino et al. investigates how the tyrosine kinase Lyn regulates the accumulation of plasma cells in rodents [1]. Using genetic engineering and mouse models, the researchers demonstrate that Lyn is a negative regulator that dampens plasma cell reactivity to cytokines. Their research sheds light on the complex mechanisms regulating these cells' homeostasis and underlines Lyn's role in regulating plasma cell accumulation. This research advances our understanding of immune system dynamics and may have clinical implications for treating plasma cell-related diseases.

Thompson and Monga discuss the WNT/-catenin signaling pathway in depth in their review article on its role in liver disease and health [2]. They discuss the role of this pathway in liver formation, regeneration, and disease progression and provide a thorough description of its essential components and regulators. Thompson and Monga provide insight into the complex relationship between WNT/-catenin signaling and liver physiology by analyzing the pertinent literature and presenting experimental data [2]. This review highlights the potential of targeting WNT/-catenin signaling for therapeutic interventions in liver diseases and expands our knowledge of liver-related processes.

Schram et al. discuss a study that looked at the safety, tolerance, and early activity of ALKS 4230 in patients with advanced solid tumors [3]. They were interested in its potential because it is a fusion protein that targets the IL-2 receptor complex. Researchers do a clinical study with a sample group of patients to determine how well ALKS 4230 works as a treatment. The results show that ALKS 4230 is safe enough to use, even though only mild side effects have been recorded. Also, some patients have demonstrated clear reactions from their tumors, suggesting that the treatment is working, at least initially. These promising results indicate that ALKS 4230 could help people with stable tumors that are about to die. The results show how vital targeted methods are in oncology and add to the ongoing work to find new ways to treat diseases.

Patients with metastatic lung cancer who have EGFR mutations are the topic of Sequist et al.'s presentation of a phase III study comparing the effectiveness and safety of afatinib, an EGFR tyrosine kinase inhibitor, to cisplatin plus pemetrexed [4]. The researchers are doing a large-scale randomized clinical study to test the effects of these therapy methods. Compared to cisplatin and pemetrexed, afatinib is a great treatment choice for people with EGFR-mutant lung adenocarcinoma because it dramatically increases progression-free survival. The study results show that using afatinib as a targeted drug for this group of patients could lead to better clinical outcomes and more personalized treatment plans.

Crizotinib is an ALK tyrosine kinase inhibitor, and in this landmark study, Solomon et al. compare its effectiveness and safety to that of chemotherapy as a first-line treatment for patients with ALK-positive lung cancer. Researchers do a large-scale randomized controlled experiment to compare how well these two treatments work [5]. The study results show that crizotinib should be the first choice treatment for people with ALK-positive lung cancer, since it improves progression-free survival and overall response rate much more than chemotherapy. When using crizotinib instead of chemotherapy,

DOI: 10.54254/2753-8818/24/20231153

some side effects happen less often than when using chemotherapy. These results show how critical targeted drugs are for improving patients' health and changing how ALK-positive lung cancer is treated.

Barlesi et al. described the results of a nationwide molecular profiling program for People with advanced NSCLC are described [6]. The study aimed to determine if systematic molecular profiling is possible and practically helpful in making treatment decisions. As the authors explain, a genomic analysis of tumor samples from a big group of patients showed many genetic mistakes, such as EGFR mutations, ALK rearrangements, and RET rearrangements. Their outcomes were better when routine molecular profiling was used to help find specific molecular abnormalities and lead targeted therapy for people with advanced NSCLC. The study's results show how crucial molecular analysis and personalized medicine are for treating lung cancer.

Camidge, Pao, and Sequist think secondary mutations, bypass signaling pathways activation, and cell structure changes cause acquired resistance [7]. They also say that it is essential to learn how resistance works so that effective countermeasures and preventive steps can be made. This book is a great way to learn about the problems with TKI therapy and the study that is still needed to find a solution to acquired resistance in lung cancer and other solid tumors.

Drilon et al. indicated results of a Phase 2 trial to test the effectiveness and safety of cabozantinib in people with advanced RET-rearranged NSCLC are described [8]. In the study, patients who had undergone platinum-based chemotherapy had good results. Overall, 28% of people answered, and 70% of the problems were solved. The study said that cabozantinib's activity could also help people with brain tumors, which are a big problem in treating NSCLC. A new study shows that patients with RET-rearranged NSCLC who are in an advanced stage may benefit from cabozantinib. This study shows how necessary targeted treatment is in specific molecular subtypes of lung cancer.

Epidermal growth factor receptor (EGFR) inhibitors are used to treat advanced non-small-cell lung cancer [9]. The authors discuss the development and efficacy of EGFR inhibitors like erlotinib and Gefitinib in treating patients with EGFR mutations. Furthermore, they highlight the significance of EGFR mutation detection in identifying potential responders to EGFR inhibitor therapy. A conventional treatment for persons with advanced NSCLC who have EGFR mutations is EGFR inhibitors, which are discussed in the book along with clinical research outcomes. This book helps expand our understanding of targeted therapies and their impact on treating non-small cell lung cancer.

Hirsch et al. discuss recent advances in targeted therapies for advanced NSCLC, providing an overview of various targeted therapy, including EGFR tyrosine kinase inhibitors (TKIs), ALK inhibitors, and inhibitors of other molecular pathways that contribute to the development and progression of NSCLC [10]. Looking for unique genetic variations within each patient is emphasized throughout the book to inform treatment options better and boost efficacy. The limitations of targeted medicines are discussed, including the development of resistance and the continual need for research into novel disease treatment methods. Other promising novel treatments for advanced NSCLC are discussed, including immune checkpoint inhibitors and combo therapy. This book is a must-have resource for treating non-small cell lung cancer patients. It informs them of recent developments in targeted therapies and how they might be used in clinical settings.

Epidermal growth factor receptor (EGFR) is a therapeutic target in non-small cell lung cancer (NSCLC). To slow the growth of non-small cell lung cancer (NSCLC) cells, Huang .et al. examined the potential of combining tyrosine kinase inhibitors (TKIs) or cetuximab, an EGFR-targeted monoclonal antibody, with RNA interference (RNAi) [11]. This study reveals that many signaling pathways can be simultaneously inhibited by combining RNAi with EGFR-targeted treatments, resulting in enhanced anticancer effects. These processes are associated with the progression of NSCLC. This book shows how combining treatments can help patients with NSCLC live longer and better lives.

Kinase inhibitors are crucial therapeutic drugs for treating NSCLC and other malignancies, and Karaman et al. provides a quantitative examination of the selectivity of kinase inhibitors [12]. The authors describe the challenges inherent in producing kinase inhibitors with high selectivity and low off-target effects. The detailed research of their selectivity profiles provides insight into the clinical utility

DOI: 10.54254/2753-8818/24/20231153

of different kinase inhibitors. This book is a treasure trove of data for scientists and doctors working on kinase inhibitors to treat NSCLC and other cancers.

Katayama et al. detail how individuals with ALK-rearranged lung cancers gain resistance to the ALK inhibitor crizotinib [13]. The authors discuss the numerous mechanisms through which cancer cells can acquire resistance to crizotinib. These include a phenotypic switch, alternate signaling pathway activation, and subsequent ALK gene mutations. In it, the authors detail the molecular mechanisms behind ALK drug resistance and show why it's critical to create next-generation ALK inhibitors or combination therapies to combat this issue. This data is crucial for developing better treatments for those with the ALK gene and lung cancer.

Kato et al. talks about the phase II trial of the EGFR inhibitor erlotinib in combination with the anti-angiogenic agent bevacizumab in patients with advanced NSCLC. In this more in-depth look at the study's safety statistics, the authors analyze and talk about how to deal with bad things that happen [14]. The study showed that the combination drug was generally safe and had side effects that were not too bad. For people with advanced NSCLC, the book emphasizes how important it is to look into the safety of drug combinations to get the best results from treatment.

Kim et al. did the ASCEND-1 study to see how well and safely the ALK inhibitor ceritinib was for people with ALK-rearranged NSCLC. The book. The efficiency of ceritinib, how long it takes to work, and any possible side effects are discussed. Participants in the study who had ALK-positive NSCLC and were given ceritinib could handle the side effects [15]. This book adds to the growing body of studies that shows that ALK inhibitors are a safe and effective way to treat non-small cell lung cancer that has ALK-rearranged.

Mille et al. show the results of the LUX-Lung 1 trial, which compared the effectiveness and safety of afatinib, an irreversible kinase inhibitor, to a placebo for patients with advanced, metastatic non-small-cell lung cancer after erlotinib, Gefitinib, or both, and one or two lines of chemotherapy failed [16]. By measuring progression-free survival, it was found that afatinib was better than a control for this group of patients who had already been through a lot of treatment. This book details how afatinib might help people with advanced NSCLC for whom usual therapies have not worked.

Mok et al. considered patients with advanced NSCLC with the EGFR T790M mutation were randomly given either osimertinib, a third-generation EGFR inhibitor, or platinum-based treatment, including pemetrexed [17]. The findings of the AURA3 trial are talked about. The results showed that progression-free mortality was much longer with osimertinib than with chemotherapy. The results show that osimertinib works against NSCLC with EGFR T790M. The book talks about what these results mean for patients and how important it is to do molecular testing to find EGFR T790M mutations to choose the best treatment. It shows how EGFR-targeted drugs are made and how osimertinib treats NSCLC that has already spread.

Wu's study goes into great detail about how crucial FDA-approved small-molecule kinase inhibitors are. The authors look at kinase inhibitors in-depth, focusing on how they work and what they can be used in the clinic [18]. The kinases talked about in this study are essential for controlling how cells work and have been linked to diseases like cancer. The piece goes into detail about the kinase inhibitors that are currently available and talks about the problems that they may face in the future. Wu et al. could be a helpful resource for scientists and doctors who want to learn more about making and using kinase inhibitors as treatments.

In this research, Zhang et al. examine how curcumin, a component of turmeric, inhibits the growth of breast cancer. Curcumin's potential impact on breast cancer cells is being studied [19]. They are especially intrigued by its potential to halt cancer progression by preventing stem cell-like features and the epithelial-to-mesenchymal transition (EMT). Zhang et al. show that treatment with curcumin suppresses the spread and invasion of breast cancer cells and lowers the expression of EMT markers using various in vitro and in vivo tests [19]. This research describes the molecular mechanism of curcumin's action and gives persuasive evidence that it may be used to treat breast cancer metastasis. This research further supports the idea that curcumin could be an effective cancer treatment.

DOI: 10.54254/2753-8818/24/20231153

The results of the IMPRESS trial, which compared the combination of Gefitinib, an EGFR inhibitor, with chemotherapy versus placebo plus chemotherapy in patients with EGFR-mutation-positive non-small-cell lung cancer after progression on first-line Gefitinib [20]. The study's goal was to ascertain the efficacy and safety of combining chemotherapy with sustained EGFR suppression in this patient population. General survival, progression-free survival, and adverse events are just some of the outcomes discussed in the book. For patients with EGFR-mutated NSCLC whose disease advances after initial treatment with an EGFR inhibitor, the data show the potential benefits of combining EGFR inhibitors with chemotherapy.

Watanabe et al. Described the use of ZSTK474 and the anti-programmed death-1 (PD-1) antibody to treat non-small cell lung cancer (NSCLC). The authors have examined how this combination treatment affects tumor growth, immune response, and signaling pathways in test tubes and living animals [21]. The book says blocking PI3K and immunological pathways is an excellent way to treat non-small cell lung cancer. The results support the idea that testing this mix in clinical studies could help people with NSCLC live longer and healthier lives.

Rosell and Karachaliou's study is awe-inspiring. In many lung cancer cases, they look for somatic mutations. Researchers look at many patient tumor samples to learn about lung cancer genetics [22]. They use cutting-edge sequencing methods to find and describe a wide range of somatic mutations that are linked to lung cancer. This helps them find the mistakes in the genes that lead to this deadly disease. By showing how different lung cancers are based on their genes, this work also points to ways to adapt treatments in the future. The result of Rosell and Karachaliou is an essential step toward figuring out how genes cause lung cancer. It also makes it possible to treat this dangerous disease with precision medicine [22].

Patients with advanced non-small-cell lung cancer who have never had chemotherapy are the focus of a critical Phase III study that compares the efficiency and safety of two chemotherapy regimens: cisplatin plus gemcitabine and cisplatin plus pemetrexed. Researchers use a large-scale, randomized, controlled study to determine how well these treatments work. The study showed that the general death rate and the number of people who responded to treatment were about the same for both plans. But cisplatin plus pemetrexed is safer than cisplatin plus gemcitabine because it causes fewer side effects. These results are helpful for doctors who study lung cancer and could change how first-line treatment regimens for advanced NSCLC are chosen [23].

The reviewed research also sheds light on the possible benefits of combining targeted agents with immunotherapy, how targeted therapies can become less effective over time, the effectiveness and safety of specific inhibitors like ALK inhibitors, EGFR inhibitors, and PI3K inhibitors, and other parts of NSCLC treatment. These researches add to what is already known and help experts, doctors, and others in health care deal with advanced NSCLC. Continuing studies and clinical trials are needed to make progress in the field and improve patient outcomes in the future.

3. Conclusion

The studies and papers that were looked at for this piece shed light on the progress and problems in treating lung cancer, with a focus on targeted therapies and molecular profiling. These studies show how crucial personalized care is for improving patients' well-being. But it's essential to be aware of the limitations of the present research, which tends to have a narrow focus and doesn't look at lung cancer from all angles. As one of the research gaps, this review found that there was a need for a more systematic and theoretical analysis of lung cancer treatment methods. Even though the studies we've discussed give us essential information about targeted treatments and how resistance works, there is still much to learn. Several things about lung cancer, like the different molecular groups and how they respond to treatment, are poorly understood. Future research should try to fill these gaps by doing more thorough and cross-disciplinary studies. Creating more effective treatment plans will be helped by a comprehensive approach that includes molecular profiling, targeted therapies, and an understanding of how resistance works. Also, because cancer is so complicated and researchers in this area have a hard time, it is essential to look into new ways of doing things that go beyond the current paradigms. In

DOI: 10.54254/2753-8818/24/20231153

conclusion, the research showed how critical personalized medicine is to treating lung cancer. But we must study a broader range of topics to learn more about the disease and develop new ways to deal with problems. By bridging these gaps and using a multidisciplinary approach, researchers can pave the way for more improvements in lung cancer treatment and, in the end, improve the outcomes for patients.

References

[1] Infantino, S., Jones, S. A., Walker, J. A., Maxwell, M. J., Light, A., O'Donnell, K., ... & Tarlinton, D. M. (2014). The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice. Science signaling, 7(338), ra77-ra77.

[2] Thompson, M. D., & Monga, S. P. (2007). WNT/β-catenin signaling in liver health and disease. Hepatology, 45(5), 1298-1305

[3] Schram AM, Gandhi L, Mita MM, et al. (2017). Safety, tolerability, and preliminary activity of ALKS 4230, an engineered fusion protein targeting the IL-2 receptor complex, in patients with advanced solid tumors. J Clin Oncol.

[4] Sequist LV, Yang JC, Yamamoto N, et al. (2013). Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol.

[5] Solomon BJ, Mok T, Kim DW, et al. (2014). First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med.

[6] Barlesi F, Mazieres J, Merlio JP, et al. (2016). Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide program of the French Cooperative Thoracic Intergroup (IFCT). Lancet.

[7] Camidge DR, Pao W, Sequist LV. (2014). Acquired resistance to TKIs in solid tumors: learning from lung cancer. Nat Rev Clin Oncol.

[8] Drilon A, Rekhtman N, Arcila M, et al. (2016). Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-center, phase 2, single-arm trial. Lancet Oncol.

[9] Gridelli C, Ardizzoni A, De Marinis F, et al. (2013). Treatment of advanced non-small-cell lung cancer patients with EGF receptor inhibitors. Cancer Treat Rev.

[10] Hirsch FR, Suda K, Wiens J, Bunn PA Jr. (2016). New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet.

[11] Huang X, Feng X, Li G, et al. (2016). Targeting epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Cancer.

[12] Karaman MW, Herrgard S, Treiber DK, et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol.

[13] Katayama R, Shaw AT, Khan TM, et al. (2012). Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med.

[14] Kato T, Seto T, Nishio M, et al. (2015). Erlotinib plus bevacizumab phase II trial in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf.

[15] Kim DW, Mehra R, Tan DS, et al. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol.

[16] Miller VA, Hirsh V, Cadranel J, et al. (2012). Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, Gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomized trial. Lancet Oncol.

[17] Mok T, Wu YL, Ahn MJ, et al. (2017). Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer. N Engl J Med.

[18] Wu P, Nielsen TE, Clausen MH. (2016). FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci.

DOI: 10.54254/2753-8818/24/20231153

[19] Zhang J, Yu J, Sun X, et al. (2016). Anti-metastasis activity of curcumin against breast cancer via inhibiting stem cell-like properties and EMT. Phytomedicine.
[20] Soria JC, Wu YL, Nakagawa K, et al. (2018). Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line Gefitinib (IMPRESS): a phase 3 randomized trial. Lancet Oncol.
[21] Watanabe S, Kimura K, Matsumoto K, et al. (2021). Preclinical Evaluation of ZSTK474, a PI3K Inhibitor, in Combination with Anti-PD-1 Antibody against Non-Small Cell Lung Cancer. Cancers.
[22] Rosell R, Karachaliou N. (2016). Large-scale screening for somatic mutations in lung cancer. Lancet.
[23] Scagliotti GV, Parikh P, von Pawel J, et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol.